Furasep0.2%

Furasep is a topical antibacterial agent used for the prevention and treatment of certain superficial bacterial infections of the skin.

Established / approved uses

• Adjunctive topical treatment of second- and third-degree burns, when clinical circumstances (e.g. hospital-acquired or resistant organisms) support use of a topical nitrofuran rather than another topical antibacterial.
• Prophylaxis against bacterial infection in surface skin lesions such as minor cuts, abrasions, and superficial wounds.
• Treatment of infected skin ulcers and superficial pyodermas caused by susceptible organisms (e.g. Staphylococcus aureus, Streptococcus species, Escherichia coli, Clostridium perfringens).
• Preparation of skin graft donor and recipient sites in burn management, as directed by a physician.

Not appropriate for

• Deep, systemic, or spreading infections — Furasep is a topical-only agent and is not a substitute for systemic antibiotic therapy when infection extends beyond the skin surface.
• Infections caused by Pseudomonas aeruginosa, which is generally not susceptible.

Use of Furasep should be guided by a physician's assessment of the wound and local infection risk.

Each Nitrofurazone topical preparation (cream, ointment, or solution) typically contains Nitrofurazone 0.2% w/w (2 mg per gram or per mL) as the active ingredient, in a water-miscible or polyethylene-glycol-based vehicle. Exact strength and base may vary slightly by manufacturer/dosage form — always check the product label.

Furasep is a synthetic nitrofuran derivative with broad-spectrum antibacterial activity against manygram-positive and gram-negative organisms commonly implicated in wound and burn-surface infections. It has been usedtopically since the mid-20th century, mainly for burn wound care and prevention of infection in minor skin lesions.

Furasep is intended for external (topical) use only. It is not effective against Pseudomonas aeruginosa andis not a treatment for deep or systemic infections.

Topical Antibacterial (Nitrofuran derivative)

Mechanism of action

Nitrofurazone is reduced by bacterial flavoproteins to reactive intermediates that damage bacterial ribosomal proteins andinterfere with several enzyme systems involved in carbohydrate metabolism (including pyruvate dehydrogenase andrelated enzymes), disrupting bacterial DNA synthesis and cellular respiration. This action is bactericidal againstsusceptible organisms.

Spectrum of activity

Nitrofurazone is active against many gram-positive organisms (e.g. Staphylococcus aureus, Streptococcusspecies) and gram-negative organisms (e.g. Escherichia coli, Enterobacter aerogenes, Proteusspecies, Clostridium perfringens) frequently found in burn wounds and skin infections. It is generallynot active against Pseudomonas aeruginosa.

Absorption

Systemic absorption through intact skin is minimal. However, absorption can increase significantly whenNitrofurazone is applied over large denuded areas (e.g. extensive burns) or under occlusive dressings, particularly inpatients with impaired renal function, due to absorption of the polyethylene glycol vehicle itself.

• For external use on the skin only — not for oral, ophthalmic, or internal use.
• Clean and gently dry the wound or affected area before applying Furasep, unless your physician directs otherwise.
• Apply a thin, even layer directly to the lesion, or apply to a sterile gauze dressing that is then placed over the wound.
• Wash hands before and after application unless applying to your own affected area only.
• Do not cover with airtight (occlusive) dressings unless specifically instructed by a physician, as this can increase absorption.
• Avoid application to the eyes, mouth, or mucous membranes.

Because Furasep is applied topically and systemic absorption through intact skin is minimal, clinically significantdrug-drug interactions are uncommon. Reported/plausible considerations include:

• Other topical agents: Avoid applying other topical antibacterial, antiseptic, or irritant products to the same site at the same time as Furasep unless directed by a physician, as this may increase local irritation or reduce effectiveness.
• Increased systemic absorption: When Furasep is used over large denuded areas (extensive burns) or under occlusive dressings, increased systemic absorption of the drug and its polyethylene glycol vehicle is possible, which can theoretically alter the handling of other concurrently administered systemic medications, particularly in patients with renal impairment.

Inform your physician or pharmacist of all other topical or systemic medicines you are using before starting Furasep.

Furasep is generally well tolerated when used as directed. Reported adverse effects are primarily local:

• Contact dermatitis and local allergic sensitization (most common with prolonged use)
• Erythema (redness) at the application site
• Pruritus (itching)
• Rash
• Local edema or inflammation
• Burning or stinging sensation on application

Discontinue Furasep and consult a physician if irritation, rash, or signs of sensitization develop or worsen. Systemicadverse effects are rare with proper external use but can occur with extensive or prolonged application (seePrecautions and Warnings).

Pregnancy: There are no well-controlled studies establishing the safety of Furasep in pregnant women.Although systemic absorption from topical use on intact, limited skin areas is expected to be minimal, Furasep should beused during pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus;consult a physician before use.

Lactation: It is not known whether topically applied Furasep is excreted in human breast milk inclinically significant amounts. Because many drugs are excreted in breast milk, caution is advised; a physician shouldbe consulted before using Furasep while breastfeeding, and application to the breast/nipple area should be avoided.

• For external use only. Avoid contact with the eyes, mouth, and other mucous membranes.
• Large surface area / occlusive use: Avoid applying Furasep over large denuded body surface areas (e.g. extensive burns) or under occlusive dressings for prolonged periods, as this increases systemic absorption of the drug and its polyethylene glycol vehicle, which has been associated with metabolic (osmolar/anion gap) disturbances, particularly in patients with impaired kidney function.
• Renal impairment: Use with particular caution and on limited body surface area in patients with significant renal impairment, due to the risk described above.
• Sensitization: Discontinue use if signs of contact dermatitis, spreading rash, or allergic sensitization develop.
• G6PD deficiency: The nitrofuran class carries a theoretical risk of hemolysis in glucose-6-phosphate dehydrogenase (G6PD) deficiency, documented mainly with systemic nitrofurantoin; as a class caution, use Furasep with care in known G6PD-deficient individuals, especially over larger treated areas.
• Not a substitute for systemic therapy: Furasep is not effective for deep, spreading, or systemic infections and should not replace systemic antibiotics when these are clinically indicated.
• Stewardship: Take/use Furasep exactly as prescribed by your physician; do not stop, extend, skip applications, or share this medicine with others without medical advice.

Topical overdose with Furasep is uncommon with normal use. Accidental ingestion or excessive/prolonged applicationover large wound or burn surfaces (especially in patients with renal impairment) may lead to systemic absorption ofthe drug and its polyethylene glycol vehicle, with possible metabolic (osmolar/anion gap) disturbances or kidneydysfunction.

If accidental ingestion occurs, or if signs of systemic toxicity (such as unusual drowsiness, reduced urine output,or unexplained illness) develop after extensive topical use, seek immediate medical attention or contact a poisoncontrol center/emergency services. Do not attempt specific home treatment for suspected overdose.

Store Furasep at room temperature (below 30°C), away from light and moisture, in a tightly closed container. Keep out of reach of children. Do not use after the expiry date printed on the pack.

Renal impairment

Use Furasep with caution and limited to smaller surface areas in patients with significant renal impairment, due to the risk of systemic absorption of the polyethylene glycol vehicle (see Precautions and Warnings).

Hepatic impairment

No specific dose adjustment is established for topical Furasep in hepatic impairment; systemic exposure is expected to remain minimal with normal use.

Elderly

No specific dose adjustment is established for elderly patients using Furasep topically; use as directed, monitoring for local skin reactions.

Burn patients

Extra caution is warranted in patients with extensive burns due to the increased risk of systemic absorption; see Precautions and Warnings.

G6PD deficiency

Use with care per class caution for nitrofuran agents (see Precautions and Warnings).

Furasep should be used for the shortest duration needed to control infection risk or support wound healing, as determined by a physician — typically until the wound is clean and healing or until re-evaluated at a follow-up visit. Prolonged, uninterrupted use (beyond a few weeks) without medical review is not recommended because of the increased risk of contact sensitization and, in extensive wounds, systemic absorption.

Nitrofurans; Topical anti-infectives/antibacterials

Furasep topical preparations may be used in children for approved external indications (minor wounds, superficialinfections, and as part of burn care under medical supervision), using the same formulations as in adults but appliedto smaller, age-appropriate areas.

Safety and efficacy in neonates and infants, and in extensive pediatric burns, have not been well established incontrolled studies; children, especially infants, have a higher body-surface-area-to-weight ratio, which may increasethe risk of systemic absorption of Furasep and its vehicle when applied over large areas. Use in children should besupervised by a physician, with smaller treated areas and close monitoring for local irritation or signs of systemiceffects.